At noon on February 11, Tuoxin Pharmaceutical announced that it intends to build a 1,000-ton-per-year nucleoside series food nutrition enhancer project, and use the super-raised funds of 59.8177 million yuan to invest in the construction of the project.
It is understood that the "1,000 tons per year nucleoside series food nutrition enhancer project" is located in Xinxiang High-tech Development Zone, including R & D center, testing center, warehouse, disodium cytidate production workshop, disodium uridate production workshop, adenylate production workshop, D-ribose production workshop, finished product c warehouse, etc. The construction period is expected to be 36 months, with a total investment of 227 million yuan, and the amount of over-raised funds to be used is 59.8177 million yuan.
Previously, Tuoxin Pharmaceutical issued 31.50 million shares of A-share shares to the public at an issue price of 19.11 yuan per share, raising a total of 600 million yuan, deducting the issuance fee of 58.6909 million yuan, and the actual net amount of funds raised was 540 million yuan, of which the over-raised funds were 147 million yuan.
Tuoxin Pharmaceutical said that after the completion of the project, according to the sales price of each product, the average annual operating income during the calculation period was 368 million yuan (excluding tax), the average annual net profit was 73.8373 million yuan, and the after-tax internal rate of return was 23.53%, while driving the development of related industries in the surrounding areas, and the project investment recovery period was 7.04 years (including the construction period).
Editor-in-charge: Chen Yuyao | Review: Li Zhen | Director: Wan Junwei
![CFHD pondered the extremely frightening plot, who actually launched the biochemical mode enhancement pod?[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)